While potty training is probably a distant childhood memory, the panicked feeling of “I need to pee right now and I don’t know if I can make it to the bathroom in time” is something many adults still ...

Sanctura XR (trospium chloride extended-release capsules), made by Indevus Pharmaceuticals, Inc., of Lexington, Mass., has been approved for the once-daily treatment of overactive bladder (OAB) with ...

The Global Female SUI Devices Market is growing due to an aging female population, rising obesity rates, and a shift towards minimally invasive treatments. Key trends include the adoption of smart ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Idiopathic overactive bladder (OAB) is a common condition in the United States, with a prevalence of 16% for men and 16.9% for women (World J Urol. 2003;20:327-336). OAB is costly, with related ...

Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign Holly Robinson Peete ...

TOKYO, Jul 23, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku ...

Behavior modification and pharmacotherapy are the mainstays of treatment for OAB. [1] Of the agents currently available, antimuscarinics are the most commonly prescribed. Within this class of drugs, ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

Osteoarthritis patients may have a higher risk of developing overactive bladder compared to those without arthritis. The study utilized NHANES data from 2005 to 2020, analyzing 24,436 participants to ...